Private Trust Company’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Private Trust Company’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-37	Closed	-$3.97K	–	2388
2023 Q1	$3.97K	Hold	37	–	–	﹤0.01%	1923
2022 Q4	$4K	Buy	+37	New	+$2.4K	﹤0.01%	1907

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Private Trust Company's RXDX Position: Q2 2023 in Review

Private Trust Company sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 37 shares — an estimated $3.97K sold.

Private Trust Company first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $4K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Private Trust Company reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Private Trust Company sold 37 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $3.97K.
Private Trust Company first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Private Trust Company's Prometheus Biosciences, Inc. Common Stock position peaked at $4K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Private Trust Company's 13F filing for Q2 2023, filed 28 Jul 2023.